Romosozumab: A Novel Injectable Sclerostin Inhibitor With Anabolic and Antiresorptive Effects for Osteoporosis.
CONCLUSIONS: Romosozumab offers an alternative for patients with a high risk of osteoporotic fractures. Clinicians should avoid romosozumab in patients with a history of myocardial infarction or stroke in the past 12 months.
PMID: 32862655 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Nealy KL, Harris KB Tags: Ann Pharmacother Source Type: research
More News: Cardiology | Cardiovascular | Clinical Trials | Drugs & Pharmacology | Forteo | Heart | Heart Attack | Orthopaedics | Osteoporosis | Stroke | Study | Women